Novartis vs ReciBioPharm: CDMO Comparison

How does Novartis compare to ReciBioPharm?

As of May 2026, Novartis: 17 FDA inspections (including 9 NAI, 8 VAI and 0 OAI), 51 EMA/MHRA GMP certificates. Signal Score 85.4. ReciBioPharm: no FDA inspections on file, 3 EMA/MHRA GMP certificates. Signal Score 82.9. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of Novartis and ReciBioPharm on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Basel, Switzerland
Signal Score
85/100
Quality (FDA + GMP)
97/100
FDA inspections
17
— NAI / VAI / OAI
9 / 8 / 0
FDA warning letters
0
EMA GMP certificates (active)
50
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
137
Capacity
—
Modalities
CAR-T, Gene Therapy
Keele, UK · Sodertalje, SE
Signal Score
83/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
3
Clinical programs (matched)
0
Capacity
—
Modalities
AAV, Lentiviral, Plasmid, mRNA

Key differences

  • Novartis has more FDA inspections on record (17 vs 0) — a deeper regulatory paper trail.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • Novartis holds 50 active EMA GMP certificates; ReciBioPharm does not appear in EudraGMDP.
  • ReciBioPharm has stronger MHRA / UK coverage (3 compliant certificates vs 1).
  • Novartis appears as a manufacturing partner on more matched clinical programs (137 vs 0) — a broader sponsor book.

Across the cross-modality scorecard, Novartis carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.

Frequently asked: Novartis vs ReciBioPharm

How does Novartis compare to ReciBioPharm?

On CDMO Signal's composite Signal Score, Novartis is 85/100 and ReciBioPharm is 83/100; Novartis has 17 FDA inspections on record vs 0 for ReciBioPharm; European coverage is 51 active EMA+MHRA certificates for Novartis vs 3 for ReciBioPharm. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, Novartis or ReciBioPharm?

Both Novartis and ReciBioPharm maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Novartis has 17 FDA inspections on record; ReciBioPharm has 0.

How do Novartis and ReciBioPharm compare on European GMP coverage?

Novartis holds 50 active EMA GMP certificates and 1 MHRA / UK certificate. ReciBioPharm holds 0 active EMA GMP certificates and 3 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is more active in clinical-stage manufacturing — Novartis or ReciBioPharm?

Novartis is matched to 137 ClinicalTrials.gov records as a manufacturing partner; ReciBioPharm is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.

What does the Signal Score gap mean in practice?

Novartis carries a Signal Score of 85/100 and ReciBioPharm carries 83/100 — essentially tied for Novartis. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Novartis and ReciBioPharm for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.